Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Vanda Pharmaceuticals Inc (NASDAQ:VNDA)

16.05
Delayed Data
As of Aug 17
 -0.25 / -1.53%
Today’s Change
11.58
Today|||52-Week Range
18.00
+0.63%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$731.2M

Company Description

Vanda Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt and Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Contact Information

Vanda Pharmaceuticals, Inc.
2200 Pennsylvania Avenue NW
Washington District Of Columbia 20037
P:(202) 734-3400
Investor Relations:
(202) 734-3428

Employees

Shareholders

Other institutional61.85%
Individual stakeholders38.29%
Mutual fund holders30.32%

Top Executives

Mihael Hristos PolymeropoulosPresident, Chief Executive Officer & Director
James Patrick KellyChief Financial Officer, Treasurer & Senior VP
Gian Piero ReverberiChief Commercial Officer & Senior Vice President
Richard L. GulinoSecretary, Senior VP & General Counsel
Gunther BirznieksVice President-Business Development